2. Search Result
Search Result
Results for "

breast adenocarcinoma

" in MedChemExpress (MCE) Product Catalog:

94

Inhibitors & Agonists

1

Fluorescent Dyes

4

Biochemical Assay Reagents

5

Peptides

10

Inhibitory Antibodies

14

Natural
Products

1

Isotope-Labeled Compounds

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146244
    Agatolimod
    1 Publications Verification

    ODN 2006; PF-3512676; CpG 7909; ODN 7909

    		 Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis Infection Cancer
    Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
    Agatolimod
  • HY-16931
    SMIFH2
    5+ Cited Publications

    		 Arp2/3 Complex Cancer
    SMIFH2 is a formin specific inhibitor. SMIFH2 inhibits actin polymerization by Formins and affects the actin cytoskeleton .
    SMIFH2
  • HY-P10944
    Unlabeled FXX489

    NNS309

    		 FAP Inflammation/Immunology Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-W075517
    ZIF-8

    2-Methylimidazole zinc salt

    		 Caspase Pyroptosis MOFs Cancer
    ZIF-8 (2-Methylimidazole zinc salt) is a caspase-1/Gasdermin D activator and a pH- and stimulus-responsive inducer of drug release, which serves as a highly efficient drug delivery carrier. ZIF-8 is a metal-organic framework (MOF). ZIF-8 activates the caspase-1/Gasdermin D-dependent pyroptosis pathway, induces pyroptosis, necrosis and immunogenic cell death, initiates in situ anti-tumor immunity, reprograms the immunosuppressive tumor microenvironment and inhibits tumor proliferation. ZIF-8 is applicable to related research on multiple cancers including colorectal cancer and breast cancer .
    ZIF-8
  • HY-152830
    Adrixetinib

    Q702

    		 c-Fms TAM Receptor MHC Cancer
    Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
    Adrixetinib
  • HY-13631J
    (1R,9R)-Exatecan mesylate

    (1R,9R)-DX8951f

    		 Drug Derivative Topoisomerase Apoptosis Cancer
    (1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative and a potent topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1R,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1R,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1R,9R)-Exatecan mesylate is widely used in preclinical studies of multiple cancers including pancreatic cancer, lung cancer, breast cancer, and leukemia . The low-activity isomer of (1R,9R)-Exatecan mesylate is (1S,9R)-Exatecan mesylate (HY-13631I).
    (1R,9R)-Exatecan mesylate
  • HY-P9974
    Vantictumab
    1 Publications Verification

    OMP-18R5

    		 Wnt Cancer
    Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
    Vantictumab
  • HY-17547
    NMS-E973
    2 Publications Verification

    		 HSP Cancer
    NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC50 of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy .
    NMS-E973
  • HY-34614
    Tricyclohexylphosphine

    Tricyclohexylphosphane

    		 Drug Intermediate Reactive Oxygen Species (ROS) Cancer
    Tricyclohexylphosphine (Tricyclohexylphosphane) is a chemical intermediate. The Tricyclohexylphosphine gold (I) n-mercaptobenzoate complex synthesized from Tricyclohexylphosphine induces ROS production and exhibits antiproliferative activity against breast cancer cells .
    Tricyclohexylphosphine
  • HY-136453
    CR-1-31-B
    Maximum Cited Publications
    11 Publications Verification

    		 Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells .
    CR-1-31-B
  • HY-P991577
    DS-8895

    DS-8895A

    		 Ephrin Receptor Cancer
    DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with 89Zr, 111In, or 125I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .
    DS-8895
  • HY-13631I
    (1S,9R)-Exatecan mesylate

    (1S,9R)-DX8951f

    		 Drug Derivative Topoisomerase Apoptosis Cancer
    (1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia .
    The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).
    (1S,9R)-Exatecan mesylate
  • HY-139434
    JMJD6-IN-1

    		Histone Demethylase Cancer
    JMJD6-IN-1 is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC50 values of 19.2 μM and 25.2 μM. JMJD6-IN-1 inhibits JMJD6 demethylase activity. JMJD6-IN-1 can be used for the research of lung adenocarcinoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer, oral squamous cell carcinoma, and glioblastoma .
    JMJD6-IN-1
  • HY-113319
    β-D-Fructose

    		Drug Intermediate Cancer
    β-D-Fructose is a monosaccharide. Derivatives synthesized using β-D-Fructose as the sugar backbone exhibit potent and selective antiproliferative activity against breast cancer MCF-7 cells .
    β-D-Fructose
  • HY-P5098
    E(c(RGDfK))2

    		Integrin Neurological Disease Cancer
    E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
    E(c(RGDfK))2
  • HY-164236
    C22 Glucosylceramide (d18:1/22:0)

    		Endogenous Metabolite Metabolic Disease
    C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .
    C22 Glucosylceramide (d18:1/22:0)
  • HY-W020955
    Triphenylphosphinechlorogold

    Chloro(triphenylphosphine)gold(I)

    		 Biochemical Assay Reagents Apoptosis DNA Alkylator/Crosslinker Lipoxygenase Cancer
    Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) is a gold complex, Apoptosis inducer, and catalyst. Triphenylphosphinechlorogold exhibits high LOX inhibitory activity. Triphenylphosphinechlorogold induces cell cycle arrest and apoptosis. Triphenylphosphinechlorogold catalyzes the peroxidation of linoleic acid. A weak interaction exists between Triphenylphosphinechlorogold and DNA. Triphenylphosphinechlorogold displays antiproliferative activity against breast cancer cells .
    Triphenylphosphinechlorogold
  • HY-141539
    SETDB1-TTD-IN-1
    5 Publications Verification

    		 Histone Methyltransferase Akt Cancer
    SETDB1-TTD-IN-1 is a SETDB1 methyltransferase activator and SETDB1-TTD competitive inhibitor (Kd of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes Akt1 Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer .
    SETDB1-TTD-IN-1
  • HY-156991
    NODAGA-NHS

    NODA-GA-NHS ester

    		 EGFR Radionuclide-Drug Conjugates (RDCs) Cancer
    NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate 64Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [ 64Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma .
    NODAGA-NHS
  • HY-147785
    Pim-1 kinase inhibitor 2
    1 Publications Verification

    		 Pim Caspase Bcl-2 Family Apoptosis Cancer
    Pim-1 kinase inhibitor 2 is a PIM-1 kinase inhibitor with a human IC50 of 0.63 μM. Pim-1 kinase inhibitor 2 exhibits high selectivity for cancer cells over normal cells. Pim-1 kinase inhibitor 2 induces apoptosis, increases active caspase-3 levels, upregulates BAX, downregulates Bcl-2, and elevates the Bax/Bcl-2 ratio. Pim-1 kinase inhibitor 2 suppresses cancer cell proliferation and induces cell cycle arrest. Pim-1 kinase inhibitor 2 can be used for the research of prostate carcinoma, hepatocellular carcinoma, and breast adenocarcinoma .
    Pim-1 kinase inhibitor 2
  • HY-142997
    DOSPA

    		Liposome Cancer
    DOSPA is a cationic lipid. DOSPA can form lipid nanoparticles with DOPE (HY-112005) to serve as a carrier for nucleic acid transfection. DOSPA is applicable in research related to drug delivery .
    DOSPA
  • HY-170859
    AH078

    		PROTACs Casein Kinase Cancer
    AH078 is a PROTAC-based CK1δ/ε degrader (DC50=0.55 μM, Dmax=70%) that lacks subtype selectivity between CK1δ and CK1ε. AH078 induces target protein degradation either by recruiting the CUL4-CRBN E3 ligase complex and proteasome, or via the VHL- and ubiquitin-dependent pathway. AH078 also exhibits selectivity for CK1α, and is widely applicable to research related to colon cancer, pancreatic cancer, breast cancer, ovarian cancer, chronic lymphocytic leukemia, acute myeloid leukemia, glioma, and metastatic breast adenocarcinoma .
    AH078
  • HY-P991481
    S-531011

    		CCR Inflammation/Immunology Cancer
    S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 + regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma .
    S-531011
  • HY-160062
    S2.2 aptamer sodium

    		Mucin Cancer
    S2.2 aptamer sodium is a nucleic acid-based MUC1-binding aptamer with high affinity and low toxicity. Upon binding to its target, S2.2 aptamer sodium undergoes a conformational switch and restores fluorescence signal, serving as a targeted imaging agent for MUC1-positive cancer cells. S2.2 aptamer sodium enables targeted delivery to breast cancer cells with overexpressed MUC1. When formulated as the S2.2-PEG-MZF molecular probe, S2.2 aptamer sodium possesses the functions of T2 signal inhibition, magnetic field-induced hyperthermia and targeted magnetic resonance molecular imaging. In the S2.2-PEG-MZF/DOX nanoliposome, S2.2 aptamer sodium supports targeted thermochemotherapy, effectively inhibiting cancer cell proliferation and invasion as well as inducing apoptosis, and is widely used in studies related to breast cancer .
    S2.2 aptamer sodium
  • HY-W014989
    Thioglucose

    		Biochemical Assay Reagents Cancer
    Thioglucose is a thiosugar with antioxidant properties. Thioglucose acts as an H2S/polysulfide donor to elevate intracellular sulfane sulfur levels and promote hydropersulfide formation. Thioglucose reduces the endocytosis of gold nanoparticles by phagocytes, enhances cytotoxicity and improves biocompatibility by increasing their adsorption on the surface of cancer cells. Thioglucose can be engineered into a stimulus-responsive prodrug or functional reagent for the development of targeted nanocarriers, and is used in studies related to human breast adenocarcinoma and cervical cancer .
    Thioglucose
  • HY-165245
    SBI-183

    		Transmembrane Glycoprotein Cancer
    SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
    SBI-183
  • HY-177043
    KAT6A/KAT7-IN-1

    		Histone Acetyltransferase Cancer
    KAT6A/KAT7-IN-1 is a KAT6A and KAT7 inhibitor with IC50 for KAT6A of within the range of 1-10 nM, and for KAT7 of ≤ 1 nM. KAT6A/KAT7-IN-1 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-1 can be used in the research of breast adenocarcinoma .
    KAT6A/KAT7-IN-1
  • HY-P991739
    RC148

    		VEGFR PD-1/PD-L1 Cancer
    RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .
    RC148
  • HY-N3741
    Didrovaltrate

    Didrovaltratum

    		 Calcium Channel Reactive Oxygen Species (ROS) Autophagy Inflammation/Immunology Cancer
    Didrovaltrate (Didrovaltratum) is an L-type calcium channel blocker, ROS scavenger, autophagy enhancer, and lipid accumulation inhibitor. Didrovaltrate blocks L-type calcium currents in a concentration-dependent manner, shifts the current-voltage curve upward, modulates steady-state inactivation kinetics, and inhibits the nuclear translocation of glucocorticoid receptors. Didrovaltrate reduces ROS levels, downregulates the expression of muscle atrophy-related genes, enhances autophagy via lipophagy, and decreases Oleic acid-induced lipid accumulation. Didrovaltrate exhibits cytotoxic activity against cancer cells. Didrovaltrate can be used in research related to skeletal muscle atrophy, non-alcoholic fatty liver disease, breast cancer, lung cancer, gastric cancer, and prostate cancer .
    Didrovaltrate
  • HY-164296
    SMP-96745

    		Drug-Linker Conjugates for ADC Cancer
    SMP-96745 is a dual-drug targeting linker-drug conjugate and can be used for study of cancer .
    SMP-96745
  • HY-N11128
    Solidagonic acid

    		Kinesin Cancer
    Solidagonic acid is an acidic bitter principle that can be found in the root and rhizomes of Solidago altissima L. Solidagonic acid binds HSET/KIFC1, restores growth in HSET-overproducing fission yeast cells and reverts mitotic spindles from monopolar to bipolar morphology. Solidagonic acid can be used for the research of breast adenocarcinoma .
    Solidagonic acid
  • HY-105314
    LY-33169

    		Others Cancer
    LY-33169 is an antitumor agent. LY-33169 had selective cytotoxicity against Colon Adenocarcinoma-38, Human Colon-116, Human Prostate LNCaP, and Human Breast WSU-Br-1 cells .
    LY-33169
  • HY-118054
    LRH-1 Inhibitor-3

    		Orphan Nuclear Receptor Cancer
    LRH-1 Inhibitor-3 is a small molecule that inhibits LRH-1 transcriptional activity, thereby decreasing the expression of target genes associated with cell growth and proliferation. LRH-1 Inhibitor-3 has shown potential in reducing cancer cell proliferation in human pancreatic, colon, and breast adenocarcinoma cell lines. LRH-1 Inhibitor-3 serves as a molecular probe for investigating the role of LRH-1 in various malignancies.
    LRH-1 Inhibitor-3
  • HY-164236S
    C22 Glucosylceramide (d18:1/22:0)-d4

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    C22 Glucosylceramide (d18:1/22:0)-d4 is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .
    C22 Glucosylceramide (d18:1/22:0)-d4
  • HY-N10777
    1-Ketoaethiopinone

    		Others Cancer
    1-Ketoaethiopinone is an abietane-diterpenoid. 1-Ketoaethiopinone has an α, β-unsaturated carbonyl function. 1-Ketoaethiopinone shows cytotoxic activity against human cancer cell lines MOLT-4 (human lymphoblastic leukemia) and MCF-7 (human breast adenocarcinoma) .
    1-Ketoaethiopinone
  • HY-152830A
    Adrixetinib TFA

    Q702 TFA

    		 c-Fms TAM Receptor MHC Cancer
    Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
    Adrixetinib TFA
  • HY-162721
    Anticancer agent 242

    		Biochemical Assay Reagents Cancer
    Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) .
    Anticancer agent 242
  • HY-149085A
    (E)-XS-060

    		RAR/RXR Cancer
    (E)-XS-060 is an isomer of XS-060. XS-060 is a RXRα antagonist. XS-060 inhibits pRXRα-PLK1 interaction. XS-060 induces RXRα-dependent mitotic arrest. XS-060 exhibits good antitumor activity against breast cancer, lung adenocarcinoma, and liver cancer .
    (E)-XS-060
  • HY-P11182
    ChMAP-28

    		Bacterial Infection Cancer
    ChMAP-28 is an antimicrobial peptide. ChMAP-28 can be derived from goat Capra hircus. ChMAP-28 can initiate necrotic death. ChMAP-28 is effective in killing many bacteria, including strains resistant to Polymyxin and Meropenem (HY-13678). ChMAP-28 shows antitumor activity against acute promyelocytic leukemia, epidermoid carcinoma, melanoma, breast adenocarcinoma .
    ChMAP-28
  • HY-172177
    ROCK/HDAC-IN-2

    		Apoptosis HDAC ROCK Cancer
    ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC50 values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .
    ROCK/HDAC-IN-2
  • HY-145866
    Antiproliferative agent-3

    		Drug Intermediate Cancer
    Antiproliferative agent-3 is an antiproliferative agent. Antiproliferative agent-3 exhibits anticancer activity against a variety of cancers, including estrogen receptor-positive breast cancer. Antiproliferative agent-3 shows no toxicity to wild-type zebrafish embryos. Antiproliferative agent-3 can be used in the research of chronic myeloid leukemia, promyelocytic leukemia, Burkitt's lymphoma, estrogen receptor-positive mammary adenocarcinoma, cervical cancer, and lung cancer .
    Antiproliferative agent-3
  • HY-151565
    Anticancer agent 86

    		Others Cancer
    Anticancer agent 86 (compound 6i) shows potential activity against breast adenocarcinoma .
    Anticancer agent 86
  • HY-138098
    Sartorypyrone B

    		Endogenous Metabolite Cancer
    Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI50s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .
    Sartorypyrone B
  • HY-151570
    Anticancer agent 87

    		Others Cancer
    Anticancer agent 87 is a potent anticancer agent. Anticancer agent 87 can be used in the research of breast adenocarcinoma and liver cancer .
    Anticancer agent 87
  • HY-N4227
    Conicasterol

    		Endogenous Metabolite Cancer
    Conicasterol is a 4-mercaptosteroid with significant cytotoxic activity. Conicasterol showed an IC50 value of 6.23 μg/mL in a test on a human breast adenocarcinoma cell line (MCF-7). Conicasterol's antitumor activity makes it a potential bioactive lead molecule .
    Conicasterol
  • HY-163947
    UG-480

    		VD/VDR Cancer
    UG-480 is a gemini analog that effectively stabilizes the active VDR conformation. UG-480 has antiproliferative effects in estrogen receptor-positive MCF-7 breast adenocarcinoma cells. UG-480 can be used in cancer research .
    UG-480
  • HY-123664
    Trioxifene mesylate

    LY133314

    		 Estrogen Receptor/ERR Cancer
    Trioxifene mesylate (LY133314) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene mesylate binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene mesylate can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma .
    Trioxifene mesylate
  • HY-17651
    PI3K-IN-60

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-60 (Compound 34) is a highly selective phosphatidylinositol 3-kinase gamma (PI3Kγ) inhibitor. PI3K-IN-60 is promising for research of autoimmune diseases (e.g., multiple sclerosis) and cancers (e.g., breast cancer, pancreatic ductal adenocarcinoma) .
    PI3K-IN-60
  • HY-179016
    Ferroptosis/apoptosis inducer-3

    		Ferroptosis Apoptosis Mitochondrial Metabolism Calcium Channel Cancer
    Ferroptosis/apoptosis inducer-3 (Compound 34) is a Ferroptosis and Apoptosis inducer. Ferroptosis/apoptosis inducer-3 induces both Ferroptosis and Apoptosis by causing G2/M phase cell cycle arrest, disrupting mitochondrial membrane potentials, promoting lipid peroxidation, and increasing the levels of Ca 2+ and Fe 2+ through the activation of calcium/calmodulin signaling. Ferraplasm/apoptosis inducer-3 shows anticancer effects against cervical cancer, adenocarcinoma, breast cancer, colon cancer, and colorectal carcinoma .
    Ferroptosis/apoptosis inducer-3
  • HY-N18083
    Gweicurculactone

    		Drug Derivative Cancer
    Gweicurculactone is a sesquiterpene and cytotoxin found in the root tuber of Curcuma wenyujin Y. H. Chen et C. Ling. Gweicurculactone exerts cytotoxic effects against human promyelocytic leukemia, hepatocellular carcinoma, chronic myelogenous leukemia, epidermoid carcinoma, and breast adenocarcinoma cells. Gweicurculactone can be used for the research of leukemia, hepatocellular carcinoma, epidermoid carcinoma of the mouth, breast adenocarcinoma .
    Gweicurculactone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: